Physician profile
Melissa D Walker
NPI 1922329424
$2,787.09
in general payments reported to CMS, 2019-2025
35 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.80 · 2022: $763 · 2023: $852 · 2024: $780 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.82 |
| Education | $297.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $321.83 | 2021-2025 | |
| Astellas Pharma US INC | $210.24 | 2022-2024 | Padcev |
| Lilly USA, LLC | $197.97 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $187.76 | 2022-2024 | Jakafi |
| Seagen INC. | $177.79 | 2022-2023 | Adcetris, Padcev |
| Janssen Biotech, INC. | $150.11 | 2022-2024 | Erleada, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $133.36 | 2023-2025 | |
| Daiichi Sankyo INC. | $105.03 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $98.73 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Esperion Therapeutics, INC. | $95.25 | 2022 | |
| Eisai INC. | $81.39 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $70.76 | 2023-2024 | Opdivo |
| Merck Sharp & Dohme LLC | $69.77 | 2022-2024 | Keytruda |
| Deciphera Pharmaceuticals INC. | $64.52 | 2023-2024 | Qinlock, Tgct |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $60.61 | 2023-2024 | Xpovio |
| Celgene Corporation | $60.07 | 2022-2023 | Pomalyst |
| Stemline Therapeutics INC. | $52.18 | 2023-2024 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $47.08 | 2022 | |
| Amgen INC. | $44.54 | 2024 | Repatha |
| Gilead Sciences, INC. | $43.43 | 2023-2024 | |
| Sobi, INC | $42.66 | 2022 | |
| Jazz Pharmaceuticals INC. | $39.77 | 2025 | |
| Genzyme Corporation | $39.30 | 2023-2024 | |
| Exelixis INC. | $37.50 | 2023 | Cabometyx |
| Caris Mpi, INC. | $35.48 | 2025 | Mi Cancer Seek |
| Becton, Dickinson and Company | $34.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $31.75 | 2025 | Lynparza |
| Genentech USA, INC. | $29.42 | 2024 | Rozlytrek, Tecentriq, Alecensa |
| Abbvie INC. | $27.90 | 2025 | |
| Geron Corporation | $21.86 | 2025 | Rytelo |
| Glaxosmithkline, LLC. | $20.86 | 2024 | Ojjaara |
| G1 Therapeutics, INC. | $20.57 | 2023 | Cosela |
| Mirati Therapeutics, INC. | $19.67 | 2023 | Krazati |
| Sumitomo Pharma America, INC. | $15.44 | 2024 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.